Known targets — ChEMBL curated mechanism
CHRM1CHRM2CHRM3CHRM4CHRM5SLC6A2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 18/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34909 | 0.90 | KDM4E (0.43) | MEN1HSP90AA1KMT2ASMN1; SMN2FDPS | |
| SCHEMBL34910 | 0.88 | KDM4E (0.43) | HTTMEN1HSP90AA1KMT2ASMN1; SMN2 | |
| SCHEMBL2295678 | 0.87 | FDPS (0.43) | HTTMEN1HSP90AA1KMT2ASMN1; SMN2 | |
| SCHEMBL34808 | 0.86 | HTT (0.42) | HTTMEN1HSP90AA1KMT2ASMN1; SMN2 | |
| SCHEMBL34270 | 0.85 | MEN1 (0.44) | MEN1HSP90AA1KMT2ASMN1; SMN2FDPS | |
| SCHEMBL34834 | 0.85 | MEN1 (0.48) | MEN1HSP90AA1KMT2ASMN1; SMN2FDPS | |
| SCHEMBL34626 | 0.84 | KDM4E (0.41) | HTTMEN1KMT2AFDPS | |
| Hydrochloric Acid SCHEMBL34818 | 0.84 | MEN1 (0.47) | MEN1HSP90AA1KMT2ASMN1; SMN2FDPS | |
| SCHEMBL16934931 | 0.82 | HTT (0.42) | HTTMEN1HSP90AA1KMT2ASMN1; SMN2 | |
| SCHEMBL34667 | 0.81 | MEN1 (0.42) | MEN1HSP90AA1KMT2ASMN1; SMN2FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2473277-B1 | PALLADIUM CATALYST SYSTEM COMPRISING ZWITTERION OR ACID-FUNCTIONALIZED IONIC LIQUID | UNIV DENMARK TECH DTU (DK) | 2019-07-03 | — | — | EP | disclosed |
| US-20170341067-A1 | Palladium Catalyst System Comprising Zwitterion And/Or Acid-Functionalyzed Ionic Liquid | UNIV DENMARK TECH DTU (DK) | 2017-11-30 | — | — | US | disclosed |
| EP-2473277-A1 | PALLADIUM CATALYST SYSTEM COMPRISING ZWITTERION AND/OR ACID-FUNCTIONALIZED IONIC LIQUID | Technical University of Denmark (DK) | 2012-07-11 | — | — | EP | disclosed |
| US-20110065950-A1 | PALLADIUM CATALYST SYSTEM COMPRISING ZWITTERION AND/OR ACID-FUNCTIONALYZED IONIC LIQUID | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2011-03-17 | — | — | US | disclosed |
| WO-2011026860-A1 | PALLADIUM CATALYST SYSTEM COMPRISING ZWITTERION AND/OR ACID-FUNCTIONALIZED IONIC LIQUID | TECHNICAL UNIVERISTY OF DENMARK (DK) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065950-A1 | PALLADIUM CATALYST SYSTEM COMPRISING ZWITTERION AND/OR ACID-FUNCTIONALYZED IONIC LIQUID | PDCD2L, PCCA, PDK2 | HTT 4211/4885MEN1 1283/4885HSP90AA1 4752/4885 |
| US-20170341067-A1 | Palladium Catalyst System Comprising Zwitterion And/Or Acid-Functionalyzed Ionic Liquid | PDCD2L, PCCA, PDK2 | HTT 4211/4885MEN1 1283/4885HSP90AA1 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.